Automated determination of free mycophenolic acid and its glucuronide in plasma from renal allograft recipients

Therapeutic Drug Monitoring

Volumn 25, Issue 3, 2003, Pages 407-414

  Mandla, Randeep ^a   Line, Pål Dag ^a   Midtvedt, Karsten ^a   Bergan, Stein ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

Author keywords

ASTED; Free fraction; Mycophenolic acid; Pharmacokinetics; Protein binding; Therapeutic drug monitoring; Transplantation

Indexed keywords

CYCLOSPORIN; DRUG METABOLITE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; MYCOPHENOLIC ACID BETA D GLUCURONIDE; STEROID; UNCLASSIFIED DRUG;

ARTICLE; AUTOMATION; COLUMN CHROMATOGRAPHY; CONTROLLED STUDY; DIALYSATE LEVEL; DIALYSIS; DRUG DETERMINATION; DRUG EFFECT; DRUG MONITORING; DRUG PROTEIN BINDING; DRUG STABILITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY TRANSPLANTATION; LIQUID CHROMATOGRAPHY; PRIORITY JOURNAL;

CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GLUCURONIDES; HUMANS; KIDNEY TRANSPLANTATION; MYCOPHENOLIC ACID; TRANSPLANTATION, HOMOLOGOUS;

EID: 0038442626     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-200306000-00025     Document Type: Article

References (14)

1. Barten MJ, van Gelder T, Gummert JF, et al. New mechanisms of action of mycophenolate mofetil in transplant recipients by assessment of its pharmacodynamics. Transplant Proc 2001;33:2254-5.
2. Weigel G, Bertalanffy P, Wolner E. Depletion of intracellular GTP results in nuclear factor-kappaB activation and intercellular adhesion molecule-1 expression in human endothelial cells. Mol Pharmacol 2002;62:453-62.
3. Oellerich M, Shipkova M, Schutz E, et al. Pharmacokinetic and metabolic investigations of mycophenolic acid in pediatric patients after renal transplantation: implications for therapeutic drug monitoring. German Study Group on Mycophenolate Mofetil Therapy in Pediatric Renal Transplant Recipients. Ther Drug Monit 2000;22:20-6.
4. Bullingham RE, Nicholls AJ, Kamm BR. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 1998;34:429-55.
5. Morissette P, Albert C, Busque S, et al. In vivo higher glucuronidation of mycophenolic acid in male than in female recipients of a cadaveric kidney allograft and under immunosuppressive therapy with mycophenolate mofetil. Ther Drug Monit 2001;23:520-5.
6. Meier-Kriesche HU, Shaw LM, Korecka M, et al. Pharmacokinetics of mycophenolic acid in renal insufficiency. Ther Drug Monit 2000;22:27-30.
7. Pou L, Brunet M, Cantarell C, et al. Mycophenolic acid plasma concentrations: influence of comedication. Ther Drug Monit 2001;23:35-8.
8. van Gelder T, Klupp J, Barten MJ, et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 2001;23:119-28.
9. Shaw LM, Holt DW, Oellerich M, et al. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001;23:305-15.
10. Johansen K, Krogh M, Andresen AT, et al. Automated analysis of free and total concentrations of three antiepileptic drugs in plasma with on-line dialysis and high-performance liquid chromatography. J Chromatogr B Biomed Appl 1995;669:281-8.
11. Shaw LM, Kaplan B, DeNofrio D, et al. Pharmacokinetics and concentration-control investigations of mycophenolic acid in adults after transplantation. Ther Drug Monit 2000;22:14-9.
12. Svensson JO, Brattström C, Säwe J. A simple HPLC method for simultaneous determination of mycophenolic acid and mycophenolic acid glucuronide in plasma. Ther Drug Monit 1999;21:322-4.
13. Nowak I, Shaw LM. Mycophenolic acid binding to human serum albumin: characterization and relation to pharmacodynamics. Clin Chem 1995;41:1011-7.
14. Kaplan B, Meier-Kriesche HU, Friedman G, et al. The effect of renal insufficiency on mycophenolic acid protein binding. J Clin Pharmacol 1999;39:715-20.